Results 31 to 40 of about 1,759,507 (251)
Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA. [PDF]
Biol Open, 2020 Infection of HIV-1 remains incurable because long-lived, latently-infected cells persist during prolonged antiretroviral therapy. Attempts to pharmacologically reactivate and purge the latent reservoir with latency reactivating agents (LRAs) such as protein kinase C (PKC) agonists (e.g. ingenol A) or histone deacetylase (HDAC) inhibitors (e.g.
Taylor JP +4 more
europepmc +5 more sources
Experimental Systems for Measuring HIV Latency and Reactivation
Viruses, 2020 The final obstacle to achieving a cure to HIV/AIDS is the presence of latent HIV reservoirs scattered throughout the body. Although antiretroviral therapy maintains plasma viral loads below the levels of detection, upon cessation of therapy, the latent ...
Koh Fujinaga, Daniele C. Cary
doaj +1 more source
Viruses, 2022 Immune cell state alterations rewire HIV-1 gene expression, thereby influencing viral latency and reactivation, but the mechanisms are still unfolding.
Emily Cruz-Lorenzo +11 more
doaj +1 more source
Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. [PDF]
Front Immunol, 2018 Antiretroviral therapy regimens durably suppress HIV replication, but do not cure infection. This is partially attributable to the persistence of long-lived pools of resting CD4+ T-cells harboring latent replication-competent virus.
Clutton GT, Jones RB.
europepmc +4 more sources
Frontiers in Microbiology, 2018 Latently infected T lymphocytes are an important barrier toward eliminating a persistent HIV infection. Here we describe an HIV-based recombinant fluorescent-lentivirus referred to as “rfl-HIV” that enables to analyze sense and antisense transcription by
Mie Kobayashi-Ishihara +17 more
doaj +1 more source
Biomedicines, 2023 Antiretroviral therapy is capable of inhibiting HIV replication, but it fails to completely achieve a cure due to HIV persistence. The commonly used HIV cure approach is the “shock and kill” strategy, which employs latency-reversing agents to trigger ...
Zhe Cong +9 more
doaj +1 more source
Optimal control of an HIV model with gene therapy and latency reversing agents [PDF]
, 2020 In this project, we study the dynamics of HIV under gene therapy and latency reversing agents. For constant treatment controls, we establish global stability of the disease-free equilibrium and endemic equilibrium based on the value of the basic ...
Hazelton, Paul, Grant, Andrew B
core +1 more source
eLife, 2018 Human immunodeficiency virus (HIV) infection is currently incurable, due to the persistence of latently infected cells. The ‘shock and kill’ approach to a cure proposes to eliminate this reservoir via transcriptional activation of latent proviruses ...
Emilie Battivelli +10 more
doaj +1 more source
eLife, 2018 An improved dual-color reporter reveals how the fate of latent HIV-1 depends on where it integrates in the human genome.
Marina Lusic
doaj +1 more source
T cell toxicity of HIV latency reversing agents
Pharmacological Research, 2019 Combination antiretroviral therapy reduces morbidity and mortality in HIV infected patients. However, the cure of HIV infection is hindered by the persistence of the latent HIV reservoir. Latency reversing agents (LRAs) are developed to target the HIV latently infected cells for HIV reactivation.
Zhao, Manzhi +7 more
openaire +2 more sources